Patents Assigned to SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
  • Patent number: 11013741
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 25, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
  • Publication number: 20210115006
    Abstract: The present invention relates to the composition and method of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 22, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Chiang Jia Li, Keith Mikule, Youzhi Li
  • Publication number: 20210107883
    Abstract: Provided herein are methods of preparation of I by reacting i with acid where R1 and R2 are each independently a leaving group. Intermediates to make i are also claimed.
    Type: Application
    Filed: November 29, 2017
    Publication date: April 15, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Jeevanandam Arumugasamy, Wei LI
  • Patent number: 10934309
    Abstract: This invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Specifically, the present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [Therein, A is O, S, or N—R6; ring G is a 5-membered or 6-membered aromatic ring, etc., including 1-3 heteroatoms selected from O, S and N as constituent atoms; R1 and R2 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, or an optionally-substituted C1-6 alkyl carbonyl group, etc.; and R6 is a hydrogen atom or an optionally-substituted C1-6 alkyl group, etc.].
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: March 2, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Hitoshi Ban, Seiji Kamioka, Shoukou Ri, Tomoyuki Furuta, Hiroyuki Kitano, Chiang Jia Li
  • Publication number: 20210052568
    Abstract: The present disclosure provides diagnostic methods useful for predicting a patient's response to alvocidib and guiding a physician decision to administer alvocidib to the patient.
    Type: Application
    Filed: March 10, 2020
    Publication date: February 25, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Steven L. WARNER, David J. Bearss
  • Publication number: 20210024482
    Abstract: The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such corn pounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof and to the pharmaceutical compositions of relevant compounds, and to the specific methods of administration of these compounds.
    Type: Application
    Filed: May 15, 2020
    Publication date: January 28, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Chiang Jia Li, Harry Rogoff, Youzhi Li, Jifeng Liu, Wei Li
  • Patent number: 10888562
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
  • Patent number: 10875864
    Abstract: The present invention provides a compound having the following structure: Compositions and methods for using the same in the treatment of skin disorders and other Pim kinase-associated conditions are also disclosed.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: December 29, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Yong Xu, Benjamin Gary Brenning, Steven G. Kultgen, Xiaohui Liu, Michael David Saunders, Koc-Kan Ho
  • Patent number: 10851075
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: December 1, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Patent number: 10835537
    Abstract: Combination therapies for treatment of cancer are provided. The disclosed methods comprise administration of a cyclin-dependent kinase inhibitor and a DNA methyltransferase inhibitor to a mammal in need thereof.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: November 17, 2020
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: David J. Bearss, Steven L. Warner, Adam Siddiqui-Jain, Clifford J. Whatcott, Wontak Kim
  • Patent number: 10766865
    Abstract: Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 8, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Koc-Kan Ho, Yong Xu, Michael David Saunders, Xiaohui Liu, Scott Albert Pearce, Kevin Bret Wright, Jason Marc Foulks, Kenneth Mark Parnell, Steven Brian Kanner, David Lee Vollmer, Jihua Liu
  • Patent number: 10752594
    Abstract: Compounds having activity as inhibitors of ALK2 kinase and/or JAK2 kinase are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, z and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: August 25, 2020
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Alexis Mollard, Steven L. Warner, Gary A. Flynn, Hariprasad Vankayalapati, David J. Bearss